Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Deciphering the melanoma-niche cell interplay to identify novel treatments for metastatic melanoma

Project description

Metastasis: the role of the tumour niche

The tumour microenvironment is emerging as a key player in disease progression and response to treatment. No wonder scientists of the MetaMelNiche project believe the tumour niche also provides cues for metastasis, one of the hallmarks of cancer associated with low survival. The project is funded by the Marie Skłodowska-Curie Actions programme and aims to investigate the interactions between melanoma and niche cells and how these may change to alter cancer cell adhesion. Using both genetic and pharmacologic approaches, researchers hope to obtain a better understanding of the mechanisms implicated in cancer cell detachment, extravasation and colonisation of distant sites. Long-term, the results of the MetaMelNiche project will open possibilities for the identification of therapeutic targets.

Objective

Metastasis is the leading cause of death among patients with solid tumours including melanoma, the most serious type of skin cancer. Despite tremendous progress in the development of effective targeted and immunotherapies, patient survival is still low. Understanding the mechanisms regulating the dissemination of cancer cells is critical to uncover new vulnerabilities of aggressive tumours. Whilst previous research has mostly focused on cell-intrinsic properties of cancer cells, the aim of this project is to define the impact of signals from the cancer cell niche on melanoma dissemination in vivo, with the long-term goal of discovering drug targets and developing new pharmacologic strategies against metastatic melanoma. Building upon previous results from the Ablain laboratory, I will elucidate and target the mechanism by which melanoma cells change their adhesion properties in response to local IGF1 signalling. Additionally, new interactions between melanoma cells and niche cells will be identified by scRNA-seq in human metastatic melanoma tissue obtained from the HCL Hospital, and recapitulated in reconstructed human skin systems and in zebrafish models. I will investigate the role of these interactions in the regulation of melanoma cell behaviour by combining genetic and pharmacologic manipulation with cutting-edge live-imaging in vitro and in vivo. This fellowship, through advanced interdisciplinary and intersectoral training and collaborations, will serve as a launchpad for reaching a position of academic independence, whilst facilitating a transfer of knowledge between myself, the CRCL and several collaborators, and addressing an unmet need for a better understanding of the behaviour of aggressive tumours. I will use this award to expand my skillset, build an international professional network, and establish myself as an expert in the field of cancer cell behaviour, producing high quality, cutting-edge research with strong translational potential.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-MSCA-2021-PF-01

See all projects funded under this call

Coordinator

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS
Net EU contribution
€ 206 364,88
Address
RUE MICHEL ANGE 3
75794 Paris
France
Region
Ile-de-France Ile-de-France Paris
Activity type
Research Organisations
Links
Total cost
No data

Partners (1)